Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD

Stopped early · Phase 3

Conditions studied: Macular Degeneration

In brief

The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.

Key facts

Study ID

NCT00065728

Run by

Alcon Research

People needed

111

Starts

2003-06-01

Expected to finish

2008-10-01

Last updated by the study team

2013-09-16

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with subfoveal exudative age-related macular degeneration (AMD) who were previously enrolled in long-term studies with anecortave acetate.
• Other protocol-defined inclusion criteria may apply.

You may not qualify if…

• Other protocol-defined exclusion criteria may apply.

Where it is running

• Belgium,France,Germany,Hungary,Italy,Netherlands,Poland,Spain,Sweden,UK — Central Contact Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.